SUWON, Republic of Korea, Sept. 24, 2020 (GLOBE NEWSWIRE) — OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, announced today the submission of an Investigational New Drug (IND) application to the US Food and
Drug Administration (FDA) to evaluate the efficacy of OLX10010 as an adjunct therapy to reduce the recurrence of hypertrophic scars after scar revision